NCT05601752
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05601752
Title ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Adaptimmune
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FRA | ESP | CAN


No variant requirements are available.